Trabectedin Intravenous and Zykadia

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. In eight study patients with advanced malignancies, administration of a single 0.58 mg/m2 infusion of trabectedin following the second dose of ketoconazole (200 mg twice daily for 15 doses), a potent CYP450 3A4 inhibitor, increased the dose-normalized mean trabectedin peak plasma concentration (Cmax) and systemic exposure (AUC) by 22% and 66%, respectively, compared to infusion of a single 1.3 mg/m2 dose of trabectedin alone. MANAGEMENT: Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Machiels JP, Staddon A, Herremans C, et al. "Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies." Cancer Chemother Pharmacol 74 (2014): 729-37 "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. In eight study patients with advanced malignancies, administration of a single 0.58 mg/m2 infusion of trabectedin following the second dose of ketoconazole (200 mg twice daily for 15 doses), a potent CYP450 3A4 inhibitor, increased the dose-normalized mean trabectedin peak plasma concentration (Cmax) and systemic exposure (AUC) by 22% and 66%, respectively, compared to infusion of a single 1.3 mg/m2 dose of trabectedin alone.

MANAGEMENT: Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.

Trabectedin Intravenous

Generic Name: trabectedin

Brand name: Yondelis

Synonyms: Trabectedin

What is Trabectedin Intravenous?

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

What is Zykadia?